AKTS (41) ORIC (29) CYRX (43) ANRO (35) ⌘ Pro Terminal →

Kura Oncology Inc. (KURA) — RQD Stock Rating Cockpit

$10.26 -2.84% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.19

Kura Oncology Inc. (KURA) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $939.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KURA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KURA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Kura Oncology Inc. (NASDAQ: KURA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $10.26 (-2.84% 1D, market cap $939.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, KURA ranks #773 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KURA compare to AKTS and ORIC in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KURA carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AKTS (Aktis Oncology Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC —, cap $937.2M) and ORIC (Oric Pharmaceuticals Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -33.4%, cap $931.8M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KURA?

▼

Per KURA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001422143), Kura Oncology Inc. generated $67.5M in revenue (+25.2% YoY), -$278.7M in net income, and -$70.7M in free cash flow against $738.4M in total assets and $9.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.19 (-0.70%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KURA)Realized 20D OHLCV Swing Band: ±10.8%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY KURA SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+10/20 pts (31% of score)

FRED Regime × Technicals: 44% of 52W Range • RSI-14 at 53.1 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (28% of score)

20D Institutional Volume Accumulation (±10.8% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$10.40-10% Next Q

Q2 (-2Q)

Grade E$9.36+2.8% Next Q

Q3 (-1Q)

Grade E$9.62+6.7% Next Q

Current

Grade E$10.26-9.2% Hist 90D α

Trajectory: D (40) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KURA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KURA currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.13) and Max Pain ($10.77) forces dealer call-delta covering toward $14.60.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KURA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “KURA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

53.130 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.20>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE44% OF RANGE

L: $7$10.26H: $14

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 2 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on KURA

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (15)

-35.0% ROIC with 42.0% gross margin and -7.53% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (40)

Altman-Z 0.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (37)

12/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like KURA

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KURA)

✓Walkthrough of KURA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KURA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +10.92%📐 HORIZONTAL RANGE

2026-11-02O $10.72H $10.72L $10.26C $10.26VOL 1.59M

RES: $15.69SUP: $8.95SMA50: $11.13SMA200: $9.81

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KURA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KURA Butterfly Map → + Track KURA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +25.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KURA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KURA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KURA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KURA)

Health Care Rank #773 of 1016 ⚔️ AKTS vs KURA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KURA vs. AKTS, ORIC, CYRX, ANRO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Kura Oncology Inc. (KURA) ranks #773 by composite RQD confidence (32/100, grade E) and #368 by equity capitalization ($939.4M). Within this direct 5-issuer industry benchmark cohort, CYRX leads on earnings valuation at 11.8x trailing P/E, while CYRX leads on capital efficiency and profitability with -11.5% ROIC and 47.1% gross margin. CYRX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with KURA at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KURA ACTIVE Kura Oncology Inc.	E	32/100	—	—	-35.0%	-2.84%	$939.4M	Benchmark Subject
AKTS Aktis Oncology Inc.	D-	41/100	—	—	—	-5.46%	$937.2M	/akts-vs-kura →
ORIC Oric Pharmaceuticals Inc.	E	29/100	—	—	-33.4%	+2.78%	$931.8M	/oric-vs-kura →
CYRX CryoPort Inc.	D-	43/100	11.8x	47.1%	-11.5%	-5.47%	$926.4M	/cyrx-vs-kura →
ANRO Alto Neuroscience Inc.	D-	35/100	—	—	-35.0%	-3.71%	$921.0M	/anro-vs-kura →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001422143

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kura Oncology Inc. (KURA) reported GAAP revenue of $67.5M (+25.2% vs. FY2024 revenue of $53.9M ) , GAAP net income of -$278.7M, operating cash flow of -$64.1M, and free cash flow of -$70.7M (-152.8% YoY). On the balance sheet, KURA closed FY2025 with $738.4M in total assets against $9.7M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$67.5M	-$278.7M	-$64.1M	-$70.7M	$738.4M	$9.7M
FY2024 (FY)	2024-12-31	$53.9M	-$174.0M	$134.3M	$133.8M	$760.2M	$6.9M
FY2023 (FY)	2023-12-31	$0	-$152.6M	-$124.8M	-$124.8M	—	—

3. KURA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KURA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does KURA compare to AKTS and ORIC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for KURA?

Where is KURA trading relative to its 50-day, 200-day, and 52-week technical levels?

KURA last traded at $10.26 (-2.84% on volume of 2,252,647 shares), positioning the stock -7.82% below its 50-day simple moving average ($11.13) and +4.59% above its 200-day simple moving average ($9.81). Across its 52-week range of $7.36 to $13.90, KURA sits at the 44.3% percentile with a 14-day RSI of 53.1 (NEUTRAL RANGE) and an implied next-earnings move of ±10.8% ($9.15 to $11.37).

KURA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell KURA stock right now?

Kura Oncology Inc. (KURA) currently earns a Roarable Rating of E (Strong Sell — SELL) with 32/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is KURA's 12-month price target and RQD AI Jury consensus?

KURA's 12-month base price target is $9.06 (range $7.07 to $14.6), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: KURA RQD Cockpit KURA 12M Forecast KURA Earnings & Move KURA Dividends & DRIP KURA Insiders & 13F KURA Whale Options KURA Profit Sankey KURA News & Why

ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

KURA — Kura Oncology Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:31:41Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating assigns KURA a score of 32 out of 100, a letter grade of E, and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." Across its five pillars:

Fundamental Cash Engine: 2 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and an FCF yield of -7.53%. For a prospective investor, the core issue is that the business is not currently generating returns on invested capital or free cash flow. Any upside case must rest on future revenue or pipeline outcomes rather than existing cash generation.
Whale 13F Flow: 9 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is below midpoint, indicating limited smart-money conviction in the current data.
Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score signals weak insider conviction in the available filings.
Macro Regime Fit: 10 / 20. Per the Roarable RQD rating, beta is 1.0 and sector sensitivity is factored in. The stock tracks the broad market without a clear macro tailwind or defensive quality.
Forensic Balance Sheet: 8 / 20. Per the Roarable RQD rating, the Altman Z-Score is 0.2, the Piotroski F-Score is 4/9, and Debt/Equity is 0.06. The low Z-Score points to elevated financial distress risk, even though leverage itself is low.

Investment implications: the valuation tradeoff is that the market is pricing a pipeline-dependent story against a loss-making income statement. The low Debt/Equity ratio reduces refinancing risk, but the weak Z-Score and negative returns mean the equity depends on continued access to capital or a successful clinical or commercial outcome. Upside drivers would be pipeline progress and a narrowing of losses; the principal downside risk is continued cash burn.

Business

Kura Oncology Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the profile. Per the market data, the company reports no gross margin (0%) and an operating margin of -60%. Per the financials, FY 2025 revenue was $67.5M. The source data does not describe specific products, customers, or the revenue model beyond these figures.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$67.5M	$-303.6M	$-278.7M	N/A	$-70.7M	$149.1M	$9.7M
FY 2024	$53.9M	$-193.2M	$-174.0M	N/A	$133.8M	$224.5M	$6.9M
FY 2023	$0.0M	$-165.8M	$-152.6M	N/A	$-124.8M	N/A	N/A

Per the SEC financials, the company has posted operating and net losses in each reported period, with net losses widening from $-152.6M (FY 2023) to $-278.7M (FY 2025). Per the market data, operating margin is -60% and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 4/9. Per the same rating, Debt/Equity is 0.06. Per the SEC financials, cash fell from $224.5M (FY 2024) to $149.1M (FY 2025) and FY 2025 free cash flow was $-70.7M.

Recent Catalysts & News Wire Analysis

Multiple wire items (CNN, Investing.com, Yahoo Finance, Seeking Alpha, TradingView, The Globe and Mail) reference KURA market action and analyst activity. The summaries are generic and do not disclose specific figures.
Per the news feed, Citizens reiterated its rating on Kura Oncology stock in connection with diabetes data.
Per the news feed, Kura Oncology launched a venture described as $50M-backed for an oral menin inhibitor in diabetes.
Per the news feed, Seeking Alpha covered KO-7246 data and the development strategy for menin inhibitors in diabetes.
Per the news feed, Bank of America Securities is described as remaining a buy on the stock.
Watch items: the diabetes-focused program represents a strategic development outside the financial data, and the source data does not quantify its expected timeline or revenue contribution.
Proprietary signals: none are listed in <butterfly_supply_chain_graph>.

Open Questions

What is the company's revenue model and source of the $67.5M FY 2025 revenue, given the 0% gross margin?
What is the cash runway implied by the $149.1M cash balance against FY 2025 free cash flow of $-70.7M?
What is the timeline and funding requirement for the diabetes venture referenced in the news feed?
Who are the institutional and insider holders, and what are their recent position changes?
What is the analyst consensus and price target range for the stock?

KURA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kura Oncology Inc. (KURA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KURA Debate Forum (3) ↓

🟡 MARKET WIRE CNN • 5h ago

symbol__ Stock Quote Price and Forecast

CNN report covering Kura Oncology Inc. (KURA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 8h ago

Citizens reiterates Kura Oncology stock rating on diabetes data

Investing.com report covering Kura Oncology Inc. (KURA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 11h ago

Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor

Yahoo Finance report covering Kura Oncology Inc. (KURA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 14h ago

Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes - Slideshow (NASDAQ:KURA) 2026-10-13

Seeking Alpha report covering Kura Oncology Inc. (KURA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 17h ago

Kura Oncology, Inc. Estimates – NASDAQ:KURA

TradingView report covering Kura Oncology Inc. (KURA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 20h ago

Bank of America Securities Remains a Buy on Kura Oncology (KURA)

The Globe and Mail report covering Kura Oncology Inc. (KURA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 23h ago

Cantor Fitzgerald reiterates Kura Oncology stock rating at Overweight

Investing.com report covering Kura Oncology Inc. (KURA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

How Kura Oncology Inc. (KURA) Affects Rotational Strategy Timing

Stock Traders Daily report covering Kura Oncology Inc. (KURA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KURA Bull vs. Bear Conversation Board — What's Your Call at $10.26?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KURA 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $9.29 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is KURA (E • RQD 32/100) a Buy at $10.56?

Welcome to the KURA (Kura Oncology Inc.) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $8.45 (-20.0%)

Spot @ $10.56

Pump the brakes on KURA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on KURA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Kura Oncology Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $12.46 (+18.0%)

Spot @ $10.56

KURA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on KURA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $10.56 (52-wk range $7.36 - $13.90), any beat on forward guidance forces shorts and underweight funds to chase.